Score Overview
Explore the 2021 public Archive ranking →
Where ImmuCell Corporation has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ICCC
2000: 79.9% · 2021: 60.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-11-17 | $ 11.33 | — |
1 Year2025-11-17 | $ 4.91 | 130.75% |
5 Years2021-11-17 | $ 9.06 | 25.00% |
10 Years2016-11-17 | $ 5.06 | 123.91% |
20 Years2006-11-17 | $ 5.35 | 111.78% |
30 Years1996-11-15 | $ 2.88 | 294.09% |
| Period | Last Price2026-11-17 | 1 Year2025-11-17 | 5 Years2021-11-17 | 10 Years2016-11-17 | 20 Years2006-11-17 | 30 Years1996-11-15 |
|---|---|---|---|---|---|---|
| Price | $ 11.33 | $ 4.91 | $ 9.06 | $ 5.06 | $ 5.35 | $ 2.88 |
| Return | — | 130.75% | 25.00% | 123.91% | 111.78% | 294.09% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 33M | $ 1M | $ 7M |
| 2025 | $ 27M | -$ 1M | $ 3M |
| 2024 | $ 26M | -$ 2M | $ 3M |
| 2023 | $ 17M | -$ 5M | $ 978.74K |
| 2022 | $ 18M | -$ 2M | $ 5M |
| 2021 | $ 19M | -$ 78.29K | $ 10M |
| 2020 | $ 15M | -$ 1M | $ 7M |
| 2019 | $ 13M | -$ 1M | $ 8M |
| 2018 | $ 10M | -$ 2M | $ 2M |
| 2017 | $ 10M | -$ 168K | $ 3M |
| 2016 | $ 9M | $ 508.45K | $ 10M |
| 2015 | $ 10M | $ 1M | $ 6M |
| 2014 | $ 7M | -$ 167.16K | $ 3M |
| 2013 | $ 6M | $ 117.39K | $ 5M |
| 2012 | $ 5M | $ 89.51K | $ 4M |
| 2011 | $ 5M | -$ 409.51K | $ 4M |
| 2010 | $ 4M | -$ 384.68K | $ 4M |
| 2009 | $ 4M | -$ 216.49K | $ 4M |
| 2008 | $ 4M | -$ 468.56K | $ 5M |
| 2007 | $ 6M | $ 662.14K | $ 5M |
| 2006 | $ 4M | $ 647.14K | $ 6M |
| 2005 | $ 4M | $ 707.78K | $ 5M |
| 2004 | $ 3M | $ 143.52K | $ 4M |
| 2003 | $ 3M | $ 411.22K | $ 4M |
| 2002 | $ 6M | $ 886.24K | $ 3M |
| 2001 | $ 6M | $ 420K | $ 1M |
| 2000 | $ 5M | $ 2M | $ 1M |
| 1999 | $ 4M | $ 550.84K | $ 1M |
| 1998 | $ 4M | -$ 100K | $ 1M |
| 1997 | $ 4M | $ 300K | $ 1M |
| 1996 | $ 4M | -$ 100K | $ 1M |
| 1995 | $ 4M | $ 1M | |
| 1994 | $ 4M | -$ 100K | $ 1M |
| 1993 | $ 3M | $ 1M | |
| 1992 | $ 3M | -$ 200K | $ 1M |
| 1991 | $ 2M | -$ 1M | $ 800K |
| 1990 | $ 3M | -$ 600K | $ 900K |
| 1989 | $ 2M | -$ 1M | $ 600K |

ImmuCell Corporation fundamental performance
Between 2020 and 2025, revenue grew from $ 15M to $ 27M and net income went from -$ 1M to -$ 1M. Revenue increased in 3 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 10M to $ 27M and net income went from $ 1M to -$ 1M. Revenue increased in 8 of those 10 years; net income in 6.
ImmuCell Corporation currently holds a 20-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Membership
Continue ICCC’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,188 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
ACADIA Pharmaceuticals IncACAD· revenue grew in 72% of years
Ligand Pharmaceuticals IncorporatedLGND· revenue grew in 70% of years
Aurinia Pharmaceuticals IncAUPH· revenue grew in 56% of years
Abbott LaboratoriesABT· revenue grew in 85% of years
Rigel Pharmaceuticals IncRIGL· revenue grew in 56% of years